VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS – the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety […]